(Q51581573)

English

Addressing the incremental benefit of histamine dihydrochloride when added to interleukin-2 in treating acute myeloid leukemia: a Bayesian meta-analysis.

scientific article published in May 2011

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/21469978

0 references

Addressing the incremental benefit of histamine dihydrochloride when added to interleukin-2 in treating acute myeloid leukemia: a Bayesian meta-analysis. (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/21469978

1 reference

based on heuristic

inferred from title

acute myeloid leukemia

1 reference

based on heuristic

inferred from title

author name string

Scott M Berry

1

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/21469978

Kristine R Broglio

2

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/21469978

Donald A Berry

3

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/21469978

publication date

1 May 2011

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/21469978

Cancer Investigation

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/21469978

29

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/21469978

4

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/21469978

293-299

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/21469978

Optimal induction and post-remission therapy for AML in first remission

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.568563

21 January 2018

Is there a role for maintenance therapy in acute myeloid leukaemia?

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.568563

21 January 2018

Current and emerging therapies for acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.568563

21 January 2018

Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.568563

21 January 2018

Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720.

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.568563

21 January 2018

Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.568563

21 January 2018

Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.568563

21 January 2018

Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.568563

21 January 2018

Bayesian clinical trials

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.568563

21 January 2018

Bayesian meta-analyses for comparative effectiveness and informing coverage decisions

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.568563

21 January 2018

Detecting an overall survival benefit that is derived from progression-free survival

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.568563

21 January 2018

Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.568563

21 January 2018

Identifiers

10.3109/07357907.2011.568563

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/21469978

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/21469978

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51581573&oldid=1521216258"